EICHOR
● Completed
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Condition: Bladder Cancer · Sponsor: Merck Sharp & Dohme LLC
About this study
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (175)
| Scripps MD Anderson ( Site 0010) | La Jolla, California, United States | — |
| Providence Saint John's Health Center ( Site 0075) | Santa Monica, California, United States | — |
| Georgetown University Medical Center ( Site 0022) | Washington D.C., District of Columbia, United States | — |
| AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005) | Orlando, Florida, United States | — |
| Parkview Cancer Institute ( Site 0077) | Fort Wayne, Indiana, United States | — |
| Indiana University Melvin and Bren Simon Cancer Center ( Site 0004) | Indianapolis, Indiana, United States | — |
| Ochsner Medical Center ( Site 0049) | New Orleans, Louisiana, United States | — |
| New England Cancer Specialists ( Site 0070) | Scarborough, Maine, United States | — |
| UMass Memorial Medical Center ( Site 0051) | Worcester, Massachusetts, United States | — |
| Henry Ford Hospital ( Site 0039) | Detroit, Michigan, United States | — |
| Mercy Hospital Saint Louis ( Site 0064) | St Louis, Missouri, United States | — |
| Morristown Medical Center ( Site 0015) | Morristown, New Jersey, United States | — |
+ 163 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.